Cirrhosis is a disease that imposes a heavy burden worldwide, but its incidence varies widely by region. Therefore, we analysed data on the incidence and mortality of cirrhosis in 204 countries and territories from 1990-2019 and projected the disease development from 2019-2039. Data on the incidence and mortality of liver cirrhosis from 1990 to 2019 were acquired from the public Global Burden of Disease (GBD) study. In addition, the average annual percentage change (AAPC) and estimated annual percentage change (EAPC) of the age-standardized rate (ASR) of cirrhosis in different regions were calculated. The estimates of risk factor exposure were summarized, and the proportion of causes and risk factors of liver cirrhosis and their relationship with the human development index (HDI) and socio-demographic index (SDI) were analysed. Trends in the incidence of cirrhosis in 2019-2039 were predicted using Nordpred and BAPC models. Globally, the ASR of cirrhosis incidence decreased by 0.05% per year from 25.7/100,000 in 1990 to 25.3/100,000 in 2019. The mortality risk associated with cirrhosis is notably lower in females than in males (13 per 100,000 vs 25 per 100,000). The leading cause of cirrhosis shifted from hepatitis B to C. Globally, alcohol use increased by 14%. In line, alcohol use contributed to 49.3% of disability-adjusted life years (DALYs) and 48.4% of global deaths from liver cirrhosis. Countries with a low ASR in 1990 experienced a faster increase in cirrhosis, whereas in 2019, the opposite was observed. In countries with high SDI, the ASR of cirrhosis is generally lower. Finally, projections indicate that the number and incidence of cirrhosis will persistently rise from 2019-2039. Cirrhosis poses an increasing health burden. Given the changing etiology, there is an imperative to strengthen the prevention of hepatitis C and alcohol consumption, to achieve early reduce the incidence of cirrhosis.
Background In adult chronic hepatitis B (CHB) patients with a favorable response to interferon therapy, an hepatitis B surface antigen (HBsAg) clearance rate exceeding 40% can be achieved. However, for the remaining population, which constitutes more than half of the HBsAg non-clearance cases, effective clinical cure options are still lacking. Therefore, in this non-randomized controlled trial, we aim to evaluate the efficacy and safety of sequential combination therapy with a programmed death receptor 1 (PD-1) inhibitor in patients who have not achieved HBsAg clearance after 48 weeks of pegylated interferon alpha (Peg-IFNα) treatment. Methods This study is a nonrandomized controlled trial. Patients with chronic hepatitis B who received Peg-IFNα treatment for 48 weeks but without HBsAg clearance were enrolled. Participants were divided into two groups on the basis of their treatment willingness. The treatment group will receive combined therapy with a PD-1 inhibitor and Peg-IFNα, whereas the Peg-IFNα regimen will be continued in the control group. All patients will also receive nucleos(t)ide analogs (NAs) antiviral therapy. Follow-up assessments will be conducted at baseline and at weeks 4, 12, and 24 to evaluate the difference in HBsAg clearance rates between the two groups and to assess the safety of a PD-1 inhibitor combined with Peg-IFNα therapy in the treatment group. The primary endpoint will be the HBsAg clearance rate at week 24. Discussion This clinical trial will elucidate the efficacy and safety of PD-1 inhibitors combined with Peg-IFNα in clearing HBsAg in CHB patients who have not been cured by interferon. Trial registration www.chictr.org.cn. Identifier: ChiCTR2400091948, Registered on 6 November 2024.